{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:51Z","timestamp":1740106911969,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T00:00:00Z","timestamp":1519430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00262-018-2127-y","type":"journal-article","created":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T07:51:34Z","timestamp":1519458694000},"page":"797-803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Certain BCG-reactive responses are associated with bladder cancer prognosis"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-5634","authenticated-orcid":false,"given":"Guang","family":"Shan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,24]]},"reference":[{"key":"2127_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21166","journal-title":"CA Cancer J Clin"},{"key":"2127_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/mi.2013.72","volume":"6","author":"MA Ingersoll","year":"2013","unstructured":"Ingersoll MA, Albert ML (2013) From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol 6:1041. \n                    https:\/\/doi.org\/10.1038\/mi.2013.72","journal-title":"Mucosal Immunol"},{"key":"2127_CR3","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","volume":"147","author":"S Prescott","year":"1992","unstructured":"Prescott S, James K, Hargreave TB et al (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147:1636\u20131642","journal-title":"J Urol"},{"key":"2127_CR4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","volume":"59","author":"M Babjuk","year":"2011","unstructured":"Babjuk M, Oosterlinck W, Sylvester R et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997\u20131008. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2011.03.017","journal-title":"Eur Urol"},{"key":"2127_CR5","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2217\/imt.10.32","volume":"2","author":"AB Alexandroff","year":"2010","unstructured":"Alexandroff AB, Nicholson S, Patel PM, Jackson AM (2010) Recent advances in Bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy 2:551\u2013560. \n                    https:\/\/doi.org\/10.2217\/imt.10.32","journal-title":"Immunotherapy"},{"key":"2127_CR6","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.juro.2008.11.124","volume":"181","author":"A Bisiaux","year":"2009","unstructured":"Bisiaux A, Thiounn N, Timsit MO et al (2009) Molecular analyte profiling of the early events and tissue conditioning following intravesical Bacillus Calmette-Guerin therapy in patients with superficial bladder cancer. J Urol 181:1571\u20131580. \n                    https:\/\/doi.org\/10.1016\/j.juro.2008.11.124","journal-title":"J Urol"},{"key":"2127_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12026-007-0084-1","volume":"39","author":"MP Simons","year":"2007","unstructured":"Simons MP, Nauseef WM, Griffith TS (2007) Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer. Immunol Res 39:79\u201393. \n                    https:\/\/doi.org\/10.1007\/s12026-007-0084-1","journal-title":"Immunol Res"},{"key":"2127_CR8","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.juro.2008.11.090","volume":"181","author":"H Takayama","year":"2009","unstructured":"Takayama H, Nishimura K, Tsujimura A et al (2009) Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical Bacillus Calmette-Guerin instillation. J Urol 181:1894\u20131900. \n                    https:\/\/doi.org\/10.1016\/j.juro.2008.11.090","journal-title":"J Urol"},{"key":"2127_CR9","doi-asserted-by":"publisher","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","volume":"4","author":"C Biot","year":"2012","unstructured":"Biot C, Rentsch CA, Gsponer JR et al (2012) Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med 4:137ra72. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3003586","journal-title":"Sci Transl Med"},{"key":"2127_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","volume":"61","author":"TCM Zuiverloon","year":"2012","unstructured":"Zuiverloon TCM, Nieuweboer AJM, V\u00e9kony H et al (2012) Markers predicting response to Bacillus Calmette-Gu\u00e9rin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61:128\u2013145. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2011.09.026","journal-title":"Eur Urol"},{"key":"2127_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.1365-2249.2002.01734.x","volume":"127","author":"J Riemensberger","year":"2002","unstructured":"Riemensberger J, B\u00f6hle A, Brandau S (2002) IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 127:20\u201326. \n                    https:\/\/doi.org\/10.1046\/j.1365-2249.2002.01734.x","journal-title":"Clin Exp Immunol"},{"key":"2127_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cyto.2006.06.009","volume":"35","author":"B Basturk","year":"2006","unstructured":"Basturk B, Yavascaoglu I, Oral B et al (2006) Cytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guerin (BCG) immunotherapy. Cytokine 35:1\u20135. \n                    https:\/\/doi.org\/10.1016\/j.cyto.2006.06.009","journal-title":"Cytokine"},{"key":"2127_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.gene.2012.09.011","volume":"511","author":"C Kucukgergin","year":"2012","unstructured":"Kucukgergin C, Isman FK, Dasdemir S et al (2012) The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. Gene 511:7\u201311. \n                    https:\/\/doi.org\/10.1016\/j.gene.2012.09.011","journal-title":"Gene"},{"key":"2127_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/QCO.0b013e328344b73e","volume":"24","author":"J-L M\u00e8ge","year":"2011","unstructured":"M\u00e8ge J-L, Mehraj V, Capo C (2011) Macrophage polarization and bacterial infections. Curr Opin Infect Dis 24:230\u2013234. \n                    https:\/\/doi.org\/10.1097\/QCO.0b013e328344b73e","journal-title":"Curr Opin Infect Dis"},{"key":"2127_CR15","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1172\/JCI59643","volume":"122","author":"A Sica","year":"2012","unstructured":"Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787\u2013795. \n                    https:\/\/doi.org\/10.1172\/JCI59643","journal-title":"J Clin Invest"},{"key":"2127_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1586\/14737140.6.12.1723","volume":"10","author":"E Pasin","year":"2008","unstructured":"Pasin E, Josephson DY, Mitra AP et al (2008) Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 10:31\u201343. \n                    https:\/\/doi.org\/10.1586\/14737140.6.12.1723","journal-title":"Rev Urol"},{"key":"2127_CR17","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1200\/JCO.2009.27.2146","volume":"28","author":"ML Disis","year":"2010","unstructured":"Disis ML (2010) Immune regulation of cancer. J Clin Oncol 28:4531\u20134538. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.27.2146","journal-title":"J Clin Oncol"},{"key":"2127_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4049\/jimmunol.172.1.61","volume":"172","author":"V Athie-Morales","year":"2003","unstructured":"Athie-Morales V, Smits HH, Cantrell DA, Hilkens CMU (2003) Sustained IL-12 signaling is required for Th1 development. J Immunol 172:61\u201369","journal-title":"J Immunol"},{"key":"2127_CR19","doi-asserted-by":"publisher","first-page":"6926","DOI":"10.1158\/1078-0432.CCR-07-1238","volume":"13","author":"ID Davis","year":"2007","unstructured":"Davis ID, Skak K, Smyth MJ et al (2007) Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res 13:6926\u20136932. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1238","journal-title":"Clin Cancer Res"},{"key":"2127_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2014.12.047","volume":"358","author":"MR Davis","year":"2015","unstructured":"Davis MR, Zhu Z, Hansen DM et al (2015) The role of IL-21 in immunity and cancer. Cancer Lett 358:107\u2013114. \n                    https:\/\/doi.org\/10.1016\/j.canlet.2014.12.047","journal-title":"Cancer Lett"},{"key":"2127_CR21","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-11-0482","volume":"17","author":"MR Zaidi","year":"2011","unstructured":"Zaidi MR, Merlino G (2011) The two faces of interferon-\u03b3 in cancer. Clin Cancer Res 17:6118\u20136124","journal-title":"Clin Cancer Res"},{"key":"2127_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1479-5876-11-37","volume":"11","author":"SJ Santegoets","year":"2013","unstructured":"Santegoets SJ, Turksma AW, Suhoski MM et al (2013) IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Transl Med 11:37. \n                    https:\/\/doi.org\/10.1186\/1479-5876-11-37","journal-title":"J Transl Med"},{"key":"2127_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","volume":"29","author":"S Crotty","year":"2011","unstructured":"Crotty S (2011) Follicular helper CD4 T cells (TFH). Annu Rev Immunol 29:621\u2013663. \n                    https:\/\/doi.org\/10.1146\/annurev-immunol-031210-101400","journal-title":"Annu Rev Immunol"},{"key":"2127_CR24","doi-asserted-by":"publisher","first-page":"e0139598","DOI":"10.1371\/journal.pone.0139598","volume":"10","author":"S Zhao","year":"2015","unstructured":"Zhao S, Wu D, Wu P et al (2015) Serum IL-10 predicts worse outcome in cancer patients: a meta-analysis. PLoS One 10:e0139598. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0139598","journal-title":"PLoS One"},{"key":"2127_CR25","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1158\/0008-5472.CAN-12-0721","volume":"72","author":"J Emmerich","year":"2012","unstructured":"Emmerich J, Mumm JB, Chan IH et al (2012) IL-10 directly activates and expands tumor-resident CD8+ T cells without De Novo infiltration from secondary lymphoid organs. Cancer Res 72:3570\u20133581. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0721","journal-title":"Cancer Res"},{"key":"2127_CR26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/bies.201300004","volume":"35","author":"JB Mumm","year":"2013","unstructured":"Mumm JB, Oft M (2013) Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-\u03b3-mediated CD8(+) T cell cytotoxicity. Bioessays 35:623\u2013631. \n                    https:\/\/doi.org\/10.1002\/bies.201300004","journal-title":"Bioessays"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2127-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2127-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2127-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T19:52:24Z","timestamp":1550951544000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2127-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,24]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2127"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2127-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2018,2,24]]},"assertion":[{"value":"14 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed and approved by the Internal Review Board of the Renmin Hospital of Wuhan University (No. RHWU10536).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"Informed consents were obtained from all participants in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}